Prime Medicine, Inc. (PRME) is a Biotechnology company in the Healthcare sector, currently trading at $3.70. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is PRME = $17 (+366.2% upside).
Valuation: PRME trades at a trailing Price-to-Earnings (P/E) of -2.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.27.
Financials: revenue is $5M, +55.3%/yr average growth. Net income is $201M (loss), growing at -21.4%/yr. Net profit margin is -4342.4% (negative). Gross margin is -58.1% (+47.3 pp trend).
Balance sheet: total debt is $116M against $121M equity (Debt-to-Equity (D/E) ratio 0.96, moderate). Current ratio is 4.84 (strong liquidity). Debt-to-assets is 34%. Total assets: $343M.
Analyst outlook: 5 / 9 analysts rate PRME as buy (56%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 21/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
